Discover upcoming breakthroughs in Type 1 Diabetes & B-cell disorder treatments, market growth to $24B by 2031, and key ...

The Indian patent, granted in a pharmaceutical market estimated at US $55 billion (Bain & Company) complements Innocan's global patent applications, strengthening the proprietary value of its ...

In early April, President Donald Trump gathered dozens of hard-hat-clad coal miners around him in the White House East Room.

Is too much matcha ever enough? Not at Sana, where matcha outsells coffee. Open since February, Sana is drawing customers from an hour away for social-media-famous matcha drinks and Asian-inspired ...

HERZLIYA, Israel and CALGARY, AB, May 6, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...

The Company reported advancing its efforts to strengthen the protection of its intellectual property across additional Asian markets, following the recently granted patent in India for a ...

"We are excited to enter the next phase of Ousia Pharma's journey, advancing our groundbreaking platform towards clinical development," said Anders B. Klein, PhD, CEO of Ousia Pharma. "The strong ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...

"We are very excited about the patent approval of our topical pain relief technology in Mexico," said Iris Bincovich, Chief Executive Officer of Innocan Pharma. Innocan Pharma intends to continue ...

GLORIA (NCT04121455) is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer ...

(Reuters) -Indian drugmaker Mankind Pharma reported a fourth-quarter profit that beat analysts' estimates on Wednesday, driven by strong domestic demand for its drugs to treat long-term illnesses. The ...